St James Hospital

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Cervical cancer1 trial
• Coronary artery disease1 trial
• Diffuse large B-cell lymphoma1 trial
• Endometrial cancer1 trial
• Head and neck cancer1 trial
• Hepatitis B1 trial
• Hepatitis C1 trial
• HIV1 trial
• Liver and biliary tract cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• and 1 more

Phase

• Phase 37 trials
• Phase 22 trials

Status

• Completed7 trials
• Active, not recruiting3 trials
• Recruiting3 trials
• Enrolling by invitation1 trial

Lead sponsor

• Hoffmann-La Roche2 trials
• Incyte Corporation2 trials
• Canadian Cancer Trials Group1 trial
• Copenhagen University Hospital, Rigshospitalet1 trial
• ECRI bv1 trial
• and 7 more

Running trials

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

  NCT06821542· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

  NCT05876754· Phase 3· Servier Affaires Médicales· Source

• Active, not recruiting

  Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  NCT05611931· Phase 3· Karyopharm Therapeutics Inc· Source

• Recruiting

  Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

  NCT03860883· Melanoma and Skin Cancer Trials Limited· Source

  Contact: Marlese Dempsey

• Enrolling by invitation

  EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV

  NCT02699736· Copenhagen University Hospital, Rigshospitalet· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Hepatitis B1 recruiting
• Hepatitis C1 recruiting
• HIV1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting

Closed trials

• Recruiting

  A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

  NCT06285318· Janssen-Cilag Ltd.· Source

• Completed

  Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization

  NCT04931771· ECRI bv· Source

• Completed

  Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

  NCT04260126· Phase 2· PDS Biotechnology Corp.· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04182204· Phase 3· Hoffmann-La Roche· Source

• Completed

  Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M

  NCT03133546· Phase 2· ETOP IBCSG Partners Foundation· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Pfizer· Source

• Completed

  Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

  NCT01658930· Canadian Cancer Trials Group· Source